RYTMRHYTHM PHARMACEUTICALS, INC.
Pharmaceutical Preparations
- Revenue
- $190M
- 46% YoY
- Operating margin
- -101.2%
- 50% YoY
- EBITDA
- −$192M
- 28% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $7M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired35% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $3M | $24M | $77M | $130M | $190M | 46% |
| Operating income | −$170M | −$179M | −$184M | −$266M | −$192M | 28% |
| Net income | −$70K | −$181K | −$185K | −$261K | −$197K | 25% |
| Operating cash flow | −$146M | −$173M | −$136M | −$114M | −$116M | 1.6% |
| Capex | $434K | $281K | $47K | $0 | $953K | |
| Stock-based comp | $21M | $20M | $33M | $40M | $67M | 68% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $5M · 5
- Net
- −$5M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $18M | $54M | 360 | 94 |
| FY2024 | $15M | $19M | 188 | 93 |
| FY2023 | $7M | $19M | 155 | 94 |
| FY2022 | $3M | $24M | 98 | 90 |
| FY2021 | $6M | −$10M | 34 | 100 |